HeartWare ventricular assist system for bridge to transplant: Combined results of the bridge to transplant and continued access protocol trial
|
|
- Melinda Foster
- 5 years ago
- Views:
Transcription
1 FEATURED ARTICLES HeartWare ventricular assist system for bridge to transplant: Combined results of the bridge to transplant and continued access protocol trial Mark S. Slaughter, MD, a Francis D. Pagani, MD, PhD, b Edwin C. McGee, MD, c Emma J. Birks, MD, a William G. Cotts, MD, c Igor Gregoric, MD, d O. Howard Frazier, MD, d Timothy Icenogle, MD, e Samer S. Najjar, MD, f Steven W. Boyce, MD, f Michael A. Acker, MD, g Ranjit John, MD, h David R. Hathaway, MD, i Kevin B. Najarian, MS, i Keith D. Aaronson, MD, MS b for the HeartWare Bridge to Transplant ADVANCE Trial Investigators From the a Division of Cardiothoracic Surgery and Department of Medicine, University of Louisville, Louisville, Kentucky; b Departments of Cardiac Surgery and Internal Medicine, University of Michigan, Ann Arbor, Michigan; c Departments of Cardiac Surgery and Internal Medicine, Northwestern University, Chicago, Illinois; d Center for Cardiac Support, Texas Heart Institute, St. Luke s Episcopal Hospital, Houston, Texas; e Northwest Cardiothoracic & Transplant Surgeons, Spokane, Washington; f Departments of Cardiac Surgery and Internal Medicine, MedStar Heart Institute, Washington Hospital Center, Washington, D.C.; g Division of Cardiothoracic Surgery, University of Pennsylvania, Philadelphia, Pennsylvania; h Division of Cardiothoracic Surgery, University of Minnesota, Minneapolis, Minnesota; and the i Clinical Affairs, HeartWare Inc, Framingham, Massachusetts. KEYWORDS: heart failure; quality of life; survival; ventricular assist device; continuous flow; bridge-to-transplant BACKGROUND: The HeartWare Ventricular Assist System (HeartWare Inc, Framingmam, MA) is a miniaturized implantable, centrifugal design, continuous-flow blood pump. The pivotal bridge to transplant and continued access protocols trials have enrolled patients with advanced heart failure in a bridge-to-transplant indication. METHODS: The primary outcome, success, was defined as survival on the originally implanted device, transplant, or explant for ventricular recovery at 180 days. Secondary outcomes included an evaluation of survival, functional and quality of life outcomes, and adverse events. RESULTS: A total of 332 patients in the pivotal bridge to transplant and continued access protocols trial have completed their 180-day primary end-point assessment. Survival in patients receiving the HeartWare pump was 91% at 180 days and 84% at 360 days. Quality of life scores improved significantly, and adverse event rates remain low. CONCLUSIONS: The use of the HeartWare pump as a bridge to transplant continues to demonstrate a high 180-day survival rate despite a low rate of transplant. Adverse event rates are similar or better than those observed in historical bridge-to-transplant trials, despite longer exposure times due to longer survival and lower transplant rates. J Heart Lung Transplant 2013;32: r 2013 International Society for Heart and Lung Transplantation. All rights reserved. Reprint requests: Mark S. Slaughter, MD, Division of Thoracic and Cardiovascular Surgery, University of Louisville, 201 Abraham Flexner Way, Ste 1200, Louisville, KY Tel.: þ Fax: address: mark.slaughter@louisville.edu /$ - see front matter r 2013 International Society for Heart and Lung Transplantation. All rights reserved. The prevalence of advanced heart failure is increasing due to enhanced survival in other cardiac diseases and to aging of the United States and European populations. In the United States alone, there are over 5 million patients with heart failure, with 660,000 new cases diagnosed each
2 676 The Journal of Heart and Lung Transplantation, Vol 32, No 7, July 2013 year. In 2008, hospital costs related to heart failure exceeded U.S. $34 billion, and 1 in 8 death certificates mentioned heart failure. 1 Overall, 50% of heart failure patients die within 4 years, and 40% of those hospitalized due to acute heart failure are readmitted or die within 1 year. 2 The gold standard for treatment of end-stage heart failure in suitable candidates is cardiac transplantation; however, donor availability is limited. Among candidates listed for transplant by United Network of Organ Sharing (UNOS) in 2010, the overall median waiting time was 6.6 months, with 12% waiting 5 years or more. 3 However, the mortality rate on the waiting list has declined during the past 12 years, from 20.7% to 13.7%, due to improvements in care, including the use of mechanical support devices. 3 The use of ventricular assist systems as a bridge to transplantation (BTT) has increased in recent years due to design enhancements leading to improved device reliability, survival, functional capacity, and quality of life. 4 6 In 2009, the number of patients that received mechanical circulatory support for BTT exceeded 30%. 7 Recently updated European Society of Cardiology guidelines for treatment of acute heart failure added the use of left ventricular assist device (LVAD) or bi-vad as a Class I/B recommendation in patients deteriorating on medical therapy while waiting for a heart transplant. 2 The American Heart Association has also issued a guidance document describing the use of mechanical circulatory support for BTT as a Class I/B recommendation, as well as providing guidance in the referral of patients for VAD support. 8 The HeartWare Ventricular Assist System (HeartWare Inc, Framington, MA) is a miniaturized, implantable centrifugal design, continuous-flow blood pump. It uses a hybrid magnetic/hydrodynamic impeller suspension for novel frictionless rotation, and optimizes flow, pump surface washing, and hemocompatibility. The HeartWare VAD (HVAD) pump is connected to lightweight patient peripherals (controller, batteries) by a thin (4.2-mm), flexible driveline with fatigueresistant cables. Compared with contemporary marketed VAD pumps, the HVAD has an integrated inflow cannula, allowing implantation within the pericardial space, and requires no abdominal surgery for formation of a pump pocket. The pump controller permits accurate flow estimation and maintains log files to enable flow and power waveform analyses. In results from the pivotal Conformité Européene Mark trial published by Strueber et al, 9 the survival rates during support were 90%, 84%, and 79% at 6, 12, and 24 months, respectively, and significantly improved measures of quality of life over baseline were noted. The pivotal ADVANCE Clinical Trial was a multicenter clinical trial to evaluate the HeartWare HVAD System for BTT in patients with advanced heart failure in the United States. The HVAD pump was implanted in 140 patients who were compared with a prospective control group of 499 patients from the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) registry who received a commercially available LVAD as a BTT. Survival in the BTT trial was 94% at 180 days and greater than 86% at 1 year, and functional capacity and quality of life improved markedly, with a favorable adverse event profile. 10 After completion of enrollment of the BTT Trial and submission to the U.S. Food and Drug Administration (FDA), an additional 256 patients were enrolled to receive an HVAD as BTT under a continued access protocol (CAP). We report here the analysis of primary and secondary end points of combined data from the 140 BTT patients plus 192 patients from CAP who were monitored to outcome or who completed at least 6 months of follow-up. Materials and methods The study design of the HVAD BTT Clinical Trial was described previously. 10 Briefly, the BTT Trial was a prospective, multicenter clinical trial to evaluate the HVAD as BTT in the United States. The trial enrolled 140 patients with advanced heart failure beginning in August 2008 who were eligible for heart transplantation at each center and were believed to be unable to survive without mechanical circulatory support. Detailed inclusion and exclusion criteria are provided in Table 1. These patients were compared with a contemporaneous control group of patients enrolled in INTER- MACS who received a commercially available LVAD as a BTT. Patients were monitored for 4180 days after implant or until cardiac transplantation, device explant for recovery, or death. The study met its primary end point, survival to 180 days on original device or transplant, demonstrating non-inferiority to the INTER- MACS control, 92% vs 88% (non-inferiority p o ). The study is ongoing, as patients will be monitored through 5 years. The FDA approved a continued access protocol (CAP) for the BTT indication for the 30 BTT clinical sites that enrolled at least 1 patient in BTT. The same enrollment criteria were in effect for the CAP as for BTT. The FDA granted 4 allotments of 54, 54, 94, and 54 additional patients under the CAP for a total of 256 patients. We present here data on the 140 patients enrolled in the ADVANCE BTT trial and an additional 192 patients enrolled under the CAP who were monitored to outcome or had completed 180 days of follow-up at the time of this analysis, July 31, The studies were conducted in compliance with FDA regulations for Good Clinical Practice, and were approved by each site s Institutional Review Board. All patients or their authorized representatives provided informed consent. Statistical analysis Descriptive statistics were used to evaluate baseline demographics, incidence rates, and changes from baseline. Continuous data are expressed as mean standard deviation. Survival is reported descriptively through Kaplan-Meier analysis, with follow-up censored at the time of heart transplantation, device explant for recovery, withdrawal of consent, or loss to follow-up. Overall survival was defined as freedom from death from any cause, with censoring at the time of heart transplant or explant for recovery. Monitoring for an outcome event continued in any patient explanted for device exchange. Competing outcomes were calculated by Kaplan-Meier nonparametric product limit actuarial method. Secondary end points included in this analysis were the incidence of all device failures and malfunctions, change in quality of life as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) Overall Summary score and the EuroQOL-5D Visual Analog Scale (EQ-5D VAS), and change in functional status as measured by the 6-minute walk test (6MWT). Values of 0 were imputed for patients unable to complete the 6MWT for any reason other than an incomplete follow-up visit.
3 Slaughter et al. Results of HVAD BTT and CAP Trials 677 Table 1 BTT + CAP Study Inclusion and Exclusion Criteria Table 1 continued Inclusion criteria 1. Must be at least 18 years of age at enrollment. 2. Body surface area 1.2 m Patient is New York Heart Association class IV. 4. Patient listed for cardiac transplantation. 5. Patient meets United Network for Organ Sharing Status 1A or 1B listing criteria. 6. HVAD implant is planned as a bridge to transplant. 7. The patient or legally authorized representative has signed the informed consent form. Exclusion criteria 1. Any ongoing mechanical circulatory support other than an intra-aortic balloon pump. 2. Prior cardiac transplant. 3. History of confirmed, untreated abdominal or thoracic aortic aneurysm 45 cm. 4. Cardiothoracic surgery within 30 days of enrollment. 5. Acute myocardial infarction within 14 days of implant as diagnosed by ST or T wave changes on the electrocardiogram, diagnostic biomarkers, ongoing pain, and hemodynamic abnormalities, as described in published guidelines. a 6. On ventilator support for 472 hours within the 4 days immediately before enrollment. 7. Pulmonary embolus within 3 weeks of enrollment as documented by computed tomography scan or nuclear scan. 8. Symptomatic cerebrovascular disease or a 480% carotid stenosis. 9. Patients with moderate to severe aortic insufficiency without plans for correction during pump implantation surgery. 10. Patients with mechanical, animal, or human tissue heart valves. 11. Severe right ventricular (RV) failure as defined by the anticipated need for RV assist device support or extracorporeal membrane oxygenation at the time of HVAD screening/enrollment or right atrial pressure 420 mm Hg on multiple inotropes, RV ejection fraction o15%, or clinical signs, including lower extremity edema, ascites or pleural effusions refractory to treatment with diuretics and 2 inotropic drugs. 12. Active, uncontrolled infection diagnosed by a combination of clinical symptoms and laboratory testing, including but not limited to, continued positive cultures, elevated temperature and white blood cell count, hypotension, tachycardia, generalized malaise despite appropriate anti-biotic, anti-viral, or anti-fungal treatment. 13. Uncorrected thrombocytopenia or generalized coagulopathy (eg, platelet count o100,000, INR 41.6, or PTT 42.5 times control in the absence of anticoagulation therapy). 14. Intolerance to anti-coagulant or anti-platelet therapies or any other peri-operative or post-operative therapy that the investigator may administer based on the patient s health status. 15. Serum creatinine 43.0 times the upper limit of normal within 48 hours of study enrollment or requiring dialysis (does not include use of ultra-filtration for fluid removal). Inclusion criteria 16. All 3 listed liver enzymes AST (SGOT), ALT (SGPT) or LDH are 43 times upper limit of normal, or a total bilirubin 43 mg/dl within 24 hours of study enrollment, or biopsy-proven liver cirrhosis or portal hypertension. 17. Pulmonary vascular resistance is unresponsive (fixed) to pharmacologic manipulation as demonstrated by a pulmonary artery systolic pressure exceeding 60 mm Hg in conjunction with any one of the three following variables: Pulmonary vascular resistance 45 Woods Units or Pulmonary vascular resistance index 46 Woods Units or Transpulmonary gradient 416 to 20 mm Hg 18. Patients requiring aortic, mitral, tricuspid or pulmonary valve replacements (including bioprosthetic valves) or left ventricular aneurysm resections. 19. Participation in any other study involving investigational drugs or devices. 20. Severe illness, other than heart disease, that would exclude cardiac transplantation. 21. Pregnancy. 22. Patient unwilling or unable to comply with study requirements. ALT, alanine aminotransferase; AST, aspartate aminotransferase; HVAD, HeartWare ventricular assist device; INR, international normalized ratio; LDH, lactate dehydrogenase; PTT, partial thromboplastin time; SGOT, serum glutamic oxaloacetic transaminase; SGPT, serum glutamic-pyruvic transaminase. a Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/ non-st-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST- Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol 2007;50:e All adverse events, including those meeting the INTERMACS definitions ( were evaluated with respect to classification and device-relatedness. Adverse event and device failures were reported as the percentage of participants affected and the rate of events per patient-year (EPPY) of follow-up. Kaplan-Meier estimates of the probability of device failures or malfunctions were also obtained. Descriptive statistics were provided for the other secondary end points and safety measures. In patients receiving warfarin, the method of Rosendaal et al 11 was used to calculate the overall time that international normalized ratio (INR) values fell within the therapeutic range. Results Baseline characteristics Between August 2008 and December 2011, 332 patients (71% men) were enrolled at 30 centers in the United
4 678 The Journal of Heart and Lung Transplantation, Vol 32, No 7, July 2013 Table 2 Baseline Demographics Characteristic a BTT and CAP BTT CAP (n ¼ 332) (n ¼ 140) (n ¼ 192) Age, years Male sex, % Race, % White Black/African American Hispanic/other Body mass index, kg/m Body surface area, m Ischemic cause of heart failure, % Left ventricular ejection fraction, % Pulmonary artery pressure, mm Hg Systolic Diastolic 24.0 þ þ Arterial blood pressure, mm Hg Systolic Diastolic Mean Central venous pressure, mm Hg (141) c (48) c (93) c Cardiac index, liters/min/m Creatinine, mmol/liter Estimated creatinine clearance, b ml/min Total bilirubin, mmol/liter Platelet count, 10 9 /liter International normalized ratio New York Heart Association class, % II III IV NA INTERMACS, % BTT, bridge to transplant; CAP, continued access protocols; INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support. a Continuous data are shown as the mean standard deviation and categoric data as indicated. b Calculated by the Cockroft-Gault formula. c Data in parentheses represents the total number of patients for which these data were available. States. Baseline demographics are described in Table 2. Patients were a mean age of years, and the mean body surface area was m 2. Heart failure due to ischemic heart disease was present in 36.7%, and 58.4% had a history of hypertension. The mean left ventricular ejection fraction was 17.4% 7.4%, and the mean cardiac index was liters/min/m 2. New York Heart Association Functional Class IV heart failure classification was recorded for 95.5% of patients. INTERMACS 4 to 7 classification was reported for 18% of patients, 42% were INTERMACS 3, 35 % were INTERMACS 2, and 5.4% were INTERMACS 1. Outcomes Patients were monitored for at least 180 days or until transplant or death. Kaplan-Meier survival analysis for the Figure 1 Survival analysis for combined HVAD bridge to transplant (BTT) and continuous access protocols (CAP; n ¼ 332).
5 Slaughter et al. Results of HVAD BTT and CAP Trials 679 Figure 2 combined BTT and CAP patients revealed survival at 60, 180, and 360 days was 97%, 91%, and 84%, respectively (Figure 1). Competing outcomes methodology showed 67.1% of patients were alive on the originally implanted study device at 180 days, and 21.4% had received a transplant or the device was explanted for recovery during this 6-month post-implant period (Figure 2). Death 180 days occurred in 6.9% of patients. Survival of patients who received a transplant or whose device was explanted for recovery after support on the HVAD was 90% at 180 days and 89% at 360 days after transplant or explant. A review of patient status through July 2012 revealed that of the 140 patients originally enrolled in the HVAD BTT Trial, 37 (26.4%) remained on support for greater than 2 years, some of whom eventually received a transplant, and 7 of these remained on support for more than 3 years. There were 55 deaths while on a mechanical support device among 332 patients in the combined cohorts, including 8 who were exchanged from the initial device for multiple reasons. The most common causes of death were neurologic events and multisystem organ failure, each occurring in 24% of patients who died. Other less frequent causes of death, by decreasing frequency, included cardiopulmonary failure (9%), infection or pneumonia (7%), right heart failure (5%), and hemorrhage, respiratory failure, and controller malfunction (4% each). Cardiac arrhythmia, hepatic failure and ischemic bowel complications led to death in less than 6% of patients. The cause of death was unknown in 13% of patients. A total of 63% of patients completed paired functional capacity measurements (6MWT) at baseline (pre-implant) and at 180 days after implant. In addition, 51% of patients completed paired KCCQ, and 54% completed paired EQ-5D VAS quality of life measurements. Of 224 patients who were available for follow-up at 6 months (ie, no transplant, device explant for recovery, or dead, and had reached the 6 month post-implant assessment), paired data were obtained on 209 for the 6 MWT, 178 for the EQ-5D VAS, and 169 for the KCCQ. Of patients completing the paired 6MWT assessments, there was a statistically significant improvement of Competing end points meters (Figure 3). The EQ-5D VAS and KCCQ Overall Summary scores showed statistically significant improvements of 27.4 and 30.9 points, respectively. Overall, there was a statistically significant improvement of 38% in the EQ-5D VAS and 46% in the KCCQ scores from baseline to 6 months (Table 3). Adverse events Adverse event rates compared favorably with historical rates with LVADs as BTT (Table 4). Follow-up time ranged from 6 to just over 36 months for patients alive on the original device. Driveline exit site infections occurred in 56 patients (16.9%), at an event rate of 0.25 EPPY, and sepsis occurred in 57 (17.2%) at 0.23 EPPY. Freedom from driveline infections and sepsis was 89% and 90% at 180 days and 83% and 80% at 1 year, respectively (Figure 4A). Bleeding requiring reoperation occurred in 49 (14.8%) at a rate of 0.19 EPPY. Gastrointestinal bleeding was identified in 42 Figure 3 Improvements in 6-minute walk test. Paired data at baseline and at 6 months after the HeartWare Ventricular Assist System implant were obtained for 209 patients for the 6-minute walk test. A value of 0 was imputed for patients unable to complete the assessment. Of patients who completed the paired 6-minute walk assessments, there was a statistically significant improvement of meters at 6 months.
6 680 The Journal of Heart and Lung Transplantation, Vol 32, No 7, July 2013 Table 3 Changes in Quality of Life in Combined Bridge to Transplant and Continued Access Protocols a Assessment Day No. Mean SD a Change p-value EQ-5D VAS VAS o0.001 KCCQ Overall Summary Overall Summary o0.001 EQ-5D, EuroQOL-5D; KCCQ, Kansas City Cardiomyopathy Questionnaire; SD, standard deviation; VAS, visual analog scale. a The EQ-5D VAS and KCCQ Overall Summary scores showed a statistically significant improvement of 38% in the EQ-5D VAS and 46% in the KCCQ from baseline to 6 months. b Value represents points. patients (12.7%), and freedom from gastrointestinal bleeding was 91% at 180 days and 86% at 1 year (Figure 4B). Cardiac tamponade was reported in 17 patients (5.1%) and cardiac arrhythmias in 120 (36.1%) with 20 patients having multiple events. Supraventricular tachycardias were more common in the perioperative period (0 30 days). Right heart failure occurred in 96 patients (28.9%), who were mostly treated with inotropic therapy. RVAD use was rarely required (3.3%). A stroke event occurred in 14.8% (2 patients having both ICVA an HCVA) of patients, and overall, 28.6% of stroke events were fatal. Ischemic cerebrovascular accidents (ICVA) occurred in 7.5% of patients, at a rate of 0.09 EPPY, and hemorrhagic CVA (HCVA) occurred in 7.8%, at a rate of 0.09 EPPY, and 46% were fatal. With respect to timing of events, 61% of ICVAs occurred after discharge, at a rate of 0.06 EPPY, and 75% of HCVAs occurred after discharge at a rate of 0.08 EPPY. Furthermore, 65% of ICVA patients had a Modified Rankin score (MRS) of 2 or less, 25% had no residual neurologic deficit (MRS, 0), and 22 of 25 patients (88%) with ICVAs survived their event. Effect of medical therapy and device design enhancements In March 2011, HeartWare reviewed anticoagulation therapy, strokes, VAD thrombus, and gastrointestinal bleeding. At that Table 4 Adverse Events in Combined Bridge to Transplant and Continued Access Protocols Events Overall (PY ¼ 305.9) (N ¼ 332) 0 30 days (PY ¼ 26.44) 430 days (PY ¼ 279.4) Patients affected Events Event rate Patients affected Events Event rate Patients affected Events Event rate %(n) (n) (PPY) % (n) (n) (PPY) % (n) (n) (PPY) Bleeding Requiring re-operation 14.8 (49) (40) (10) Gastrointestinal 12.7 (42) (11) (36) Infections Driveline exit site 16.9 (56) (9) (49) Sepsis 17.2 (57) (10) (48) Arrhythmia Ventricular 20.8 (69) (34) (39) Supraventricular 21.4 (71) (49) (28) Renal dysfunction 9.6 (32) (17) (17) Hepatic dysfunction 4.8 (16) (6) (10) Respiratory dysfunction 22.0 (73) (53) (26) Hemolysis a 1.2 (4) (3) (1) 1 0 Device exchanges Procedure-related 2.1 (7) (7) (0) 0 0 Suspected thrombus 4.2 (14) (1) (13) Other 2.4 (8) (1) (7) Neurologic events CVA Ischemic 7.5 (25) (11) (16) Hemorrhagic 7.8 (26) (7) (19) TIA 4.8 (16) (5) (11) Right heart failure Inotropic therapy 25.0 (83) (69) (17) RVAD 3.3 (11) (9) (2) Inhaled nitric oxide 1.2 (4) (4) (0) 0 0 Venous thromboembolism 6.3 (21) (11) (10) Arterial embolism 1.5 (5) (1) (4) CVA, cerebrovascular accident; PY, patient-year; PPY, per patient-year; RVAD, right ventricular assist device; TIA, transient ischemic attack. a Hemolysis includes non-thrombus events only.
7 Slaughter et al. Results of HVAD BTT and CAP Trials 681 use of the higher dose of ASA ( mg) rose from 54% to 67%. A shift also occurred in the median time in therapeutic INR range ( ) from 35% to 46%. The annualized rate of pump exchange for suspected thrombus dropped from to 0.027, a level 55% less than the rate before the anticoagulation adjustment (Figure 5). During the same interval (after March 15, 2011, through July 30, 2012), the incidence of ischemic strokes resulting in any disability (MRS 4 0) declined as well (Table 5). The incidence of ischemic strokes resulting in any level of neurologic disability declined from 5.1% (0.089 EPPY) to 2.8% (0.047 EPPY). The incidence of hemorrhagic strokes resulting in any level of neurologic disability was relatively unchanged, from 5.1% (0.082 EPPY) to 4.7% (0.074 EPPY). Discussion Figure 4 Freedom from (A) driveline and sepsis infections and (B) gastrointestinal bleeding in patients on HeartWare ventricular assist device (HVAD) pump support. time, device exchanges occurred at a rate of 0.07 EPPY. Specifically, procedure-related device exchanges occurred at a rate of 0.01 PPY, whereas suspected thrombus-related device exchange occurred at PPY. Most patients with VAD thrombus (1) had sub-therapeutic INRs and (2) were taking 81 mg aspirin or no acetylsalicylic acid (ASA). Moreover, the rates of bleeding or hemorrhagic strokes in patients with therapeuticinrscombinedwithasaat325mg/daywerenot higher than those patients who were at sub-therapeutic levels. Hence, the Principal Investigators recommended in March 2011 that strict adherence to the protocol INR requirement of 2.0 to 3.0 be followed and that the ASA dose be advanced to 325 mg. After March 15, 2011, and through July 30, 2012, the These data continue to support the findings from the HVAD BTT pivotal trial regarding the safety and efficacy of the HVAD pump in patients with end-stage heart failure requiring an LVAD as a BTT. Overall survival remains high, at 91% at 180 days and 84% at 1 year, despite lower transplant rates than in prior BTT trials. 12,13 Survival also compares favorably or better than survival rates published with other commercially available VADs for BTT, including survival after transplant Patients with advanced heart failure experience significant impairment in quality of life and functional capacity. Improved survival and longer waiting times for transplant after LVAD implantation means quality of life and functional capacity outcomes are especially important. Quality of life and functional capacity were substantially improved at 6 months in recipients of the HVAD. The distance walked in the 6MWT more than tripled, and statistically significant improvements of 84% and 62% were observed in the KCCQ and in the EQ-5D VAS scores from baseline to 6 months, respectively. These functional and quality of life improvements are similar to those reported in the HeartMate II (Thoratec, Pleasanton, CA) BTT Trial. 6 Adverse event rates remain low and are similar to those published with the currently approved device, the HeartMate Table 5 Incidence of Strokes Before and After Stricter Anti-coagulation and Introduction of an Enhanced Coring Tool and Sintered Inflow Cannula Event Overall BTT þ CAP (N ¼ 332) Patients with event o03/15/2011 a EPPY 403/15/2011 a EPPY %(n) ( years) % (n) ( years) All ICVAs 6.3 (16/253) (10/211) ICVAs with MRS 4 0 b 5.1 (13/253) (6/211) All HCVAs 5.1 (13/253) (14/211) HCVAs with MRS 4 0 b 5.1 (13/253) (10/211) BTT, bridge to transplant; CAP, continued access protocols; EPPY, events per patient-year; HCVA, hemorrhagic cerebrovascular accident; ICVA, ischemic cerebrovascular accident; MRS, Modified Rankin score a Patients whose follow-up crossed the time periods were included in both denominators. b Determined at 4 to 8 weeks after stroke.
8 682 The Journal of Heart and Lung Transplantation, Vol 32, No 7, July 2013 Figure 5 Exchange rates for suspected pump thrombus were analyzed for those events occurring prior to the anticoagulation adjustment and device design enhancements (on or before March 15, 2011) compared to those occurring post adjustment and design enhancements (after March 15, 2011 through July 30, 2012). Total patients at risk pre-adjustment was n ¼ 253, and the total number at risk post-adjustment was n ¼ 211. II Strokes, thrombus, and cardiac arrhythmias are similar, but bleeding and infections are lower compared with the HeartMate II BTT and CAP published data. 13,14 Specifically, driveline infections and sepsis were very low, occurring at rates of 0.25 and 0.23 EPPY, respectively (Table 4 and Figure 4). Bleeding requiring transfusions or reoperations was very low compared with published rates, occurring at an overall rate of only 0.19 EPPY each, whereas gastrointestinal bleeding was observed at a rate of 0.27 EPPY. In the HeartMate II BTT Trial, Miller et al 14 reported that an ICVA occurred in 6% of (0.13 EPPY) and an HCVA in 2% (0.05 EPPY). Later in the CAP trial, Pagani et al 13 reported ICVAs in 5% of patients (0.09 EPPY) and HCVAs in 3% (0.05 EPPY). The fatality rate of all strokes occurring in the HeartMate II CAP trial was 40% (10 of 25), whereas the fatality rate after an HCVA was 56% (5 of 9). 13 We observed an overall stroke fatality rate of only 28.6% in the BTT and CAP trials using the HVAD and a 46% mortality rate after an HCVA. Furthermore, 25% of patients with an ICVA fully recovered, with no residual neurological deficits (MRS, 0) and 88% (22 of 25) survived their event. A review of the anti-coagulation and anti-platelet medication data during CAP enrollment prompted recommendation of an adjustment of the daily aspirin dose from 81 to 325 mg and a request to target the maintenance INR range to 2.0 to 3.0. Pump exchange rates for suspected pump thrombus decreased by 55% to very low levels after this change in recommended anticoagulation and aspirin therapy (Figure 5). Moreover, ischemic strokes with any level of disability (MRS 40) declined from 5.1% (0.089 EPPY) to 2.8% (0.047 EPPY; Table 5). Aspirin and anti-coagulation therapy use with the HVAD was without an increased risk of bleeding complications. Our data thus indicate that patients receiving a HVAD as a BTT have excellent 6-month and 1-year survival, significant improvements in quality of life, and adverse event rates comparable to or lower than those reported in comparable clinical trials, including a very low exchange rate for VAD thrombus. In the course of the study, a reduction in the incidence of strokes and device exchanges due to suspected thrombus was observed after adjustments in clinical anti-coagulation management. This study has several limitations. First, this was not a randomized trial; all patients received the HVAD. However, at the time of initiation of the HVAD BTT trial, the HeartMate II was not yet approved, and clinicians were reluctant to implant the FDA-approved XVE device due to its relatively large size, poor durability, and adverse event profile. HeartWare and FDA determined that using a sufficiently large sub-set of INTERMACS patients would be an appropriate comparator to the HVAD treatment arm. Another limitation is that adverse event rates can only be compared with historical literature. However, the contemporaneous control from the INTERMACS database was limited in its availability of reported adverse event rates. The reference data sets in publications from controlled studies of the HeartMate II in the BTT population supports the hypothesis that the HVAD is at least as safe as the commercially available LVADs. In conclusion, the ongoing data from the CAP cohort of the HVAD BTT trial continue to support the overall survival, significantly improved quality of life, and overall safety and reliability of the HVAD system in patients with end-stage heart failure requiring a BTT. Rates of bleeding, infections and device exchanges due to thrombus were very low, and the survival of patients going on to cardiac transplantation was excellent. Ongoing patient management strategies have decreased the incidence of device exchanges and disabling strokes, and continue to result in improved patient outcomes in this population. Disclosure statement This study is registered at with the Unique Identifier NCT The authors acknowledge Mary V. Jacoski, HeartWare Inc, for her assistance in the preparation of the manuscript. M.S.S. receives education and training grant support from HeartWare Inc and Thoratec Corp. F.D.P. receives grant support HeartWare Inc. E.C.M., M.A.A., and R.J. are consultants for HeartWare Inc and Thoratec Corp. S.W.B. is a stockholder in HeartWare Inc and Thoratec Corp. D.R.H. and K.N. are employees of HeartWare Inc. K.D.A. receives research grant support from HeartWare Inc. None of the other authors has a financial relationship with a commercial entity that has an interest in the subject of the presented manuscript or other conflicts of interest to disclose. References 1. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics 2008 update. Circulation 2008;117:e McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33: Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR). OPTN/SRTR 2010 annual data report. Washington, DC: Department of Health and Human Services, Healthcare Systems Bureau, Division of Transplantation; 2011.
9 Slaughter et al. Results of HVAD BTT and CAP Trials Park SJ, Kushwaha SS, McGregor CGA. State-of-the-art implantable cardiac assist device therapy for heart failure: bridge to transplant and destination therapy. Clin Pharmacol Ther 2012;91: Lund LH, Matthews J, Aaronson K. Patient selection for left ventricular assist devices. Eur J Heart Fail 2010;12: Rogers JG, Aaronson KD, Boyle AJ, et al. Continuous flow left ventricular assist device improves functional capacity and quality of life of advanced heart failure patients. J Am Coll Cardiol 2010;55: Stehlik J, Edwards LB, Kucheryavaya AY, et al. The registry of the International Society for Heart and Lung Transplantation: twentyeighth adult heart transplant report J Heart Lung Transplant 2011;30: Peura JL, Colvin-Adams M, Francis GS, et al. Recommendations for the use of mechanical circulatory support: device strategies and patient selection. Circulation 2012;126: Strueber M, O Driscoll G, Jansz P, et al. Multicenter evaluation of an intrapericardial left ventricular assist system. J Am Coll Cardiol 2011;57: Aaronson KD, Slaughter MS, Miller LW, et al. Use of an intrapericardial, continuous flow, centrifugal pump in patients awaiting heart transplantation. Circulation 2012;125: Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993;69: John R, Naka Y, Smedira NG, et al. continuous flow left ventricular assist device outcomes in commercial use compared with the prior clinical trial. Ann Thorac Surg 2011;92: Pagani FD, Miller LW, Russell SD, et al. Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. J Am Coll Cardiol 2009;54: Miller LW, Pagani FD, Russell SD, et al. Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med 2007;357: Boyle AJ, Russell SD, Teuteberg JJ, et al. Low thromboembolism and pump thrombosis with the HeartMate II left ventricular assist device: analysis of outpatient anti-coagulation. J Heart Lung Transplant 2009;28: Starling RC, Naka Y, Boyle AJ, et al. Results of the post-u.s. Food and Drug Administration-approval study with a continuous flow left ventricular assist device as a bridge to heart transplantation: a prospective study using the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardiol 2011;57: Backes D, van den Bergh WM, van Duijn AL, Lahpor JR, van Dijk D, Slooter AJ. Cerebrovascular complications of left ventricular assist devices. Eur J Cardiothorac Surg 2012;42:
HeartWare ADVANCE Bridge to Transplant Trial and Continued Access Protocol Update
HeartWare ADVANCE Bridge to Transplant Trial and Continued Access Protocol Update Mark S. Slaughter, MD University of Louisville, KY, USA HeartWare Users Meeting 29 October 2012 Barcelona, Spain HEARTWARE,
More informationDestination Therapy SO MUCH DATA IN SUCH A SMALL DEVICE. HeartWare HVAD System The ONLY intrapericardial VAD approved for DT.
DT Destination Therapy SO MUCH DATA IN SUCH A SMALL DEVICE. HeartWare HVAD System The ONLY intrapericardial VAD approved for DT. ONLY WE HAVE THIS BREADTH OF CLINICAL EVIDENCE TO SUPPORT DESTINATION THERAPY.
More informationMulticenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 (MOMENTUM 3) Long Term Outcomes
Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with (MOMENTUM 3) Long Term Outcomes Mandeep R. Mehra, MD, Daniel J. Goldstein, MD, Nir Uriel, MD, Joseph
More informationHEARTMATE 3 LVAD WITH FULL MAGLEV FLOW TECHNOLOGY THEIR FUTURE STARTS WITH YOU
HEARTMATE 3 WITH FULL MAGLEV FLOW TECHNOLOGY THEIR FUTURE STARTS WITH YOU HEARTMATE 3 with Full MagLev Flow Technology HEARTMATE 3 DELIVERS UNPRECEDENTED * SURVIVAL AND SAFETY OUTCOMES **1 LANDMARK SURVIVAL
More informationHEARTMATE 3 LEFT VENTRICULAR ASSIST SYSTEM
HEARTMATE 3 LEFT VENTRICULAR ASSIST SYSTEM A New Milestone in LVAD Therapy HeartMate 3 Left Ventricular Assist Device Introducing the new HEARTMATE 3 LVAD WITH FULL MAGLEV FLOW TECHNOLOGY HeartMate 3 LVAD
More informationContinuous Flow Left Ventricular Assist Device Outcomes in Commercial Use Compared With the Prior Clinical Trial
Continuous Flow Left Ventricular Assist Device Outcomes in Commercial Use Compared With the Prior Clinical Trial Ranjit John, MD, Yoshifumi Naka, MD, Nicholas G. Smedira, MD, Randall Starling, MD, MPH,
More informationMechanical Circulatory Support in the Management of Heart Failure
Mechanical Circulatory Support in the Management of Heart Failure Feras Bader, MD, MS, FACC Associate Professor of Medicine Director, Heart Failure and Transplant Cleveland Clinic Abu Dhabi Chairman, Heart
More informationA Fully Magnetically Levitated Left Ventricular Assist Device. Final Report of the MOMENTUM 3 Trial
A Fully Magnetically Levitated Left Ventricular Assist Device Final Report of the MOMENTUM 3 Trial Mandeep R. Mehra, MD, Nir Uriel, MD, Joseph C. Cleveland, Jr., MD, Daniel J. Goldstein, MD, National Principal
More informationIntrapericardial Left Ventricular Assist Device for Advanced Heart Failure
The new england journal of medicine Original Article Intrapericardial Left Ventricular Assist Device for Advanced Heart Failure Joseph G. Rogers, M.D., Francis D. Pagani, M.D., Ph.D., Antone J. Tatooles,
More informationRecent Trials With Durable LVADs: Is There a Superior Device?
Recent Trials With Durable LVADs: Is There a Superior Device? Francis D. Pagani MD PhD Otto Gago MD Endowed Professor of Cardiac Surgery Michigan Medicine Current Device Landscape 2018 HeartMate 3 HeartMate
More informationIs it time to consider a HEARTMATE LEFT VENTRICULAR ASSIST DEVICE (LVAD)?
Is it time to consider a HEARTMATE LEFT VENTRICULAR ASSIST DEVICE (LVAD)? A treatment for advanced heart failure. LAURA HeartMate II LVAD Recipient What is HEART FAILURE? Heart failure sometimes called
More informationStatus of Implantable VADs
Status of Implantable VADs John V. Conte, MD, Professor of Surgery Johns Hopkins University School of Medicine Division of Cardiac Surgery The Johns Hopkins Medical Institutions Conflict of Interest Statement
More informationHEARTMATE II LEFT VENTRICULAR ASSIST SYSTEM. HeartMate II Left Ventricular Assist Device
HEARTMATE II LEFT VENTRICULAR ASSIST SYSTEM HeartMate II Left Ventricular Assist Device HeartMate II Left Ventricular Assist Device UNPARALLELED REAL-WORLD EXPERIENCE Over 25,000 heart failure patients
More informationJournal of the American College of Cardiology Vol. 60, No. 1, by the American College of Cardiology Foundation ISSN /$36.
Journal of the American College of Cardiology Vol. 60, No. 1, 2012 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.02.031
More informationLIVING A MORE ACTIVE LIFE. with the HeartMate 3 LVAD for the treatment of advanced heart failure RON. Recipient
LIVING A MORE ACTIVE LIFE with the HeartMate 3 LVAD for the treatment of advanced heart failure RON HeartMate 3 LVAD Recipient What is HEART FAILURE? Heart failure sometimes called a weak heart occurs
More informationLVAD Complications, Recovery
LVAD Complications, Recovery Abbas Ardehali, M.D., F.A.C.S. Professor of Surgery and Medicine, Division of Cardiac Surgery William E. Connor Chair in Cardiothoracic Transplantation Director, UCLA Heart,
More informationCHANGING THE WAY HEART FAILURE IS TREATED. VAD Therapy
CHANGING THE WAY HEART FAILURE IS TREATED VAD Therapy VAD THERAPY IS BECOMING AN ESSENTIAL PART OF HEART FAILURE PROGRAMS AROUND THE WORLD. Patients with advanced heart failure experience an impaired quality
More informationAdverse Event. Adverse Event Status. Please enter the date of the event you are reporting: Please enter a label describing this event:
Adverse Event Adverse Event Status Please enter the date of the event you are reporting: Please enter a label describing this event: 1 of 17 Adverse Event Infection Was there a major infection? Date of
More informationVentricular Assist Devices for Permanent Therapy: Current Status and Future
Ventricular Assist Devices for Permanent Therapy: Current Status and Future Prospects Francis D. Pagani MD PhD Professor of Cardiac Surgery University of Michigan April 28 th, 2012 Disclosures NHLBI and
More informationDisclosures. No disclosures to report
Disclosures No disclosures to report Update on MOMENTUM 3 Trial: The Final Word? Francis D. Pagani MD PhD Otto Gago MD Professor of Cardiac Surgery University of Michigan Ann Arbor, Michigan, USA LVAD
More informationHeart Transplant vs Left Ventricular Assist Device in Heart Transplant-Eligible Patients
Heart Transplant vs Left Ventricular Assist Device in Heart Transplant-Eligible Patients Matthew L. Williams, MD, Jaimin R. Trivedi, MD, MPH, Kelly C. McCants, MD, Sumanth D. Prabhu, MD, Emma J. Birks,
More informationAdverse Event - Intermacs
version date: 6/28/2017 Adverse Event - Intermacs Adverse Event Status Please enter the date of the event you are reporting: Please enter a label describing this event: 1 of 24 version date: 6/28/2017
More informationRisk Factors for Adverse Outcome after HeartMate II Jennifer Cowger, MD, MS St. Vincent Heart Center of Indiana
Risk Factors for Adverse Outcome after HeartMate II Jennifer Cowger, MD, MS St. Vincent Heart Center of Indiana Advanced Heart Failure, Transplant, & Mechanical Circulatory Support Relevant Financial Relationship
More informationLessons learned from ENDURANCE, ROADMAP, MedaMACS, and how to go forward?
Lessons learned from ENDURANCE, ROADMAP, MedaMACS, and how to go forward? Mark S. Slaughter, MD Professor and Chair Department of Cardiovascular and Thoracic Surgery University of Louisville What could
More informationAnalysis of Pump Thrombosis in the Intermacs Database
Analysis of Pump Thrombosis in the Intermacs Database Michael Acker William Measey Professor of Surgery Chief of Division of Cardiovascular Surgery Director of Heart and Vascular Center University of Pennsylvania
More informationOverview of MCS in Bruce B Reid, MD Surgical Director Artificial Heart Program/Heart Transplantation
Overview of MCS in 2017 Bruce B Reid, MD Surgical Director Artificial Heart Program/Heart Transplantation Technology Embracing Progress Technology Adoption Internet Adoption of Technology Pioneer in the
More informationMulticenter Evaluation of an Intrapericardial Left Ventricular Assist System
Journal of the American College of Cardiology Vol. 57, No. 12, 2011 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2010.10.040
More informationLeft Ventricular Assist Devices (LVADs): Overview and Future Directions
Left Ventricular Assist Devices (LVADs): Overview and Future Directions FATIMA KARAKI, M.D. PGY-3, DEPARTMENT OF MEDICINE WASHINGTON UNIVERSITY IN ST. LOUIS ST. LOUIS, MISSOURI, USA St. Louis, Missouri,
More informationRecognition & Treatment of Right Ventricular Failure
Recognition & Treatment of Right Ventricular Failure Robert L Kormos MD, FRCS(C), FACS, FAHA Deputy Director McGowan Institute for Regenerative Medicine Brack G Hattler Chair of Cardiothoracic Transplantation
More informationAllinaHealthSystem 1
: Definition End-organ hypoperfusion secondary to cardiac failure Venoarterial ECMO: Patient Selection Michael A. Samara, MD FACC Advanced Heart Failure, Cardiac Transplant & Mechanical Circulatory Support
More informationBridge to Heart Transplantation
Bridge to Heart Transplantation Ulf Kjellman MD, PhD Senior Consultant Surgeon Heart Centre KFSH&RC 1 Disclosure Appointed for Proctorship by Thoratec/St.Jude/Abbott 2 To run a full overall covering transplant
More informationFifth INTERMACS annual report: Risk factor analysis from more than 6,000 mechanical circulatory support patients
http://www.jhltonline.org SPECIAL FEATURE Fifth INTERMACS annual report: Risk factor analysis from more than 6, mechanical circulatory support patients James K. Kirklin, MD, a David C. Naftel, PhD, a Robert
More informationISHLT 35 th Annual Meeting and Scientific Sessions th April, 2015, Nice, France
HeartWare HVAD for the Treatment of Patients with Advanced Heart Failure Ineligible for Cardiac Transplantation: Results of the ENDURANCE Destination Therapy Trial FD Pagani 1, CA Milano 2, AJ Tatooles
More informationImplantable Ventricular Assist Devices and Total Artificial Hearts. Policy Specific Section: June 13, 1997 March 29, 2013
Medical Policy Implantable Ventricular Assist Devices and Total Artificial Hearts Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Surgery Original Policy Date: Effective
More informationAdverse Event. Adverse Event Status. version date: 12/10/ of 21. Please enter the date of the event you are reporting:
version date: 12/10/2015 Adverse Event Adverse Event Status Please enter the date of the event you are reporting: Please enter a label describing this event: 1 of 21 version date: 12/10/2015 Adverse Event
More informationAdverse Event - Pedimacs
version date: 12/19/2017 Adverse Event - Pedimacs Adverse Event Status Please enter the date of the event you are reporting: Please enter a label describing this event: 1 of 22 version date: 12/19/2017
More informationModern Left Ventricular Assist Devices (LVAD) : An Intro, Complications, and Emergencies
Modern Left Ventricular Assist Devices (LVAD) : An Intro, Complications, and Emergencies ERIC T. ROME D.O. HEART FAILURE, MECHANICAL ASSISTANCE AND TRANSPLANTATION CVI Left Ventricular Assist Device An
More informationMinimally Invasive Insertion of HVAD
Minimally Invasive Insertion of HVAD Simon Maltais, MD PhD Vice-Chair of Clinical Practice Director of MCS Program Department of Cardiovascular Surgery Mayo Clinic, Rochester, MN AATS MCS 2018, Houston
More informationECMO as a Bridge to Heart Transplant in the Era of LVAD s.
Christian Bermudez MD. Associate Professor Director Thoracic Transplantation Division Cardiac Surgery Department of Surgery University of Pennsylvania ECMO as a Bridge to Heart Transplant in the Era of
More informationAdvances in Advanced Heart Failure Therapies. Disclosures. Management Algorithm for Patients in Cardiogenic Shock
Advances in Advanced Heart Failure Therapies 9 th Annual Dartmouth Conference on Advances in Heart Failure Therapies Dartmouth-Hitchcock Medical Center May 20, 2013 Joseph G. Rogers, M.D. Associate Professor
More informationAlliance A Symptomatic brain radionecrosis after receiving radiosurgery for
RANDOMIZED PHASE II STUDY: CORTICOSTEROIDS + BEVACIZUMAB VS. CORTICOSTEROIDS + PLACEBO (BEST) FOR RADIONECROSIS AFTER RADIOSURGERY FOR BRAIN METASTASES Pre-registration Eligibility Criteria Required Initial
More informationUpdate on Mechanical Circulatory Support. AATS May 5, 2010 Toronto, ON Canada
Update on Mechanical Circulatory Support AATS May 5, 2010 Toronto, ON Canada Disclosures NONE Emergency Circulatory Support ECMO Tandem Heart Impella Assessment Cardiac Function Pulmonary function Valvular
More informationNone. Declaration of conflict of interest
None Declaration of conflict of interest New Long Term Circulatory Support Technology and Treatment Strategies Stephen Westaby Oxford, UK Cardiac Transplantation: Facts from the UNOS Database Median survival
More informationThe Balancing Act Bleeding and Thrombosis in MCS. Muhammad Adil Soofi
The Balancing Act Bleeding and Thrombosis in MCS Muhammad Adil Soofi Road Map Survival and complications with LVAD What is the Burden of thrombosis and bleeding Why Bleeding and Thrombosis happen When
More informationMechanical Support in the Failing Fontan-Kreutzer
Mechanical Support in the Failing Fontan-Kreutzer Stephanie Fuller MD, MS Thomas L. Spray Endowed Chair in Congenital Heart Surgery Associate Professor, The Perelman School of Medicine at the University
More informationInitial clinical experience with a novel left ventricular assist device with a magnetically levitated rotor in a multi-institutional trial
http://www.jhltonline.org FEATURED ARTICLES Initial clinical experience with a novel left ventricular assist device with a magnetically levitated rotor in a multi-institutional trial Georg M. Wieselthaler,
More informationMechanical Circulatory Support (MCS): What Every Pharmacist Needs to Know!
Mechanical Circulatory Support (MCS): What Every Pharmacist Needs to Know! Matthew A. Wanat, PharmD, BCPS, BCCCP, FCCM Clinical Assistant Professor University of Houston College of Pharmacy Clinical Pharmacy
More informationORIGINAL ARTICLE. Alexander M. Bernhardt a, *, Theo M.M.H. De By b, Hermann Reichenspurner a and Tobias Deuse a. Abstract INTRODUCTION
European Journal of Cardio-Thoracic Surgery 48 (2015) 158 162 doi:10.1093/ejcts/ezu406 Advance Access publication 29 October 2014 ORIGINAL ARTICLE Cite this article as: Bernhardt AM, De By TMMH, Reichenspurner
More informationNovel Devices for End-Stage Heart Failure
Novel Devices for End-Stage Heart Failure Lynne Warner Stevenson No conflicts of interest Off-label assist devices and expanded indications will be discussed Devices for End-Stage Heart Failure New definitions
More informationWhen to implant VAD in patients with heart transplantation indication. Aldo Cannata Dept of Cardiac Surgery Niguarda Ca Granda Hospital Milano
When to implant VAD in patients with heart transplantation indication Aldo Cannata Dept of Cardiac Surgery Niguarda Ca Granda Hospital Milano LVAD strategies In waiting list? Goal Bridge to transplant
More informationSeventh INTERMACS annual report: 15,000 patients and counting
http://www.jhltonline.org INTERMACS ANNUAL REPORT Seventh INTERMACS annual report: 15,000 patients and counting James K. Kirklin, MD, a David C. Naftel, PhD, a Francis D. Pagani, MD, PhD, b Robert L. Kormos,
More informationWhat has INTERMACS Taught Us about Patient Outcomes with Durable MCS? James K. Kirklin, MD
What has INTERMACS Taught Us about Patient Outcomes with Durable MCS? James K. Kirklin, MD Disclosure: I am Director of the Data Coordinating Center for the INTERMACS project and receive support through
More informationUnderstanding the Pediatric Ventricular Assist Device
Understanding the Pediatric Ventricular Assist Device W. James Parks, MSc., MD Pediatric Cardiologist Assistant Professor of Pediatrics and Radiology Children s Healthcare of Atlanta Sibley Heart Center
More informationConcomitant Aortic Valve Procedures in Patients Undergoing Implantation of Continuous-Flow LVADs: An INTERMACS Database Analysis
Concomitant Aortic Valve Procedures in Patients Undergoing Implantation of Continuous-Flow LVADs: An INTERMACS Database Analysis April 11, 2014 Jason O. Robertson, M.D., M.S.; David C. Naftel, Ph.D., Sunil
More informationPredicting Survival in Patients Receiving Continuous Flow Left Ventricular Assist Devices
Journal of the American College of Cardiology Vol. 61, No. 3, 2013 2013 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.09.055
More informationExtended Mechanical Circulatory Support With a Continuous-Flow Rotary Left Ventricular Assist Device
Journal of the American College of Cardiology Vol. 54, No. 4, 2009 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.03.055
More informationUniversity of Wisconsin - Madison Cardiovascular Medicine Fellowship Program UW CICU Rotation Goals and Objectives
Background: The field of critical care cardiology has evolved considerably over the past 2 decades. Contemporary critical care cardiology is increasingly focused on the management of patients with advanced
More informationYes No Unknown. Major Infection Information
Rehospitalization Intervention Check any that occurred during this hospitalization. Pacemaker without ICD ICD Atrial arrhythmia ablation Ventricular arrhythmia ablation Cardioversion CABG (coronary artery
More informationMechanical Cardiac Support in Acute Heart Failure. Michael Felker, MD, MHS Associate Professor of Medicine Director of Heart Failure Research
Mechanical Cardiac Support in Acute Heart Failure Michael Felker, MD, MHS Associate Professor of Medicine Director of Heart Failure Research Disclosures Research Support and/or Consulting NHLBI Amgen Cytokinetics
More informationRamani GV et al. Mayo Clin Proc 2010;85:180-95
THERAPIES FOR ADVANCED HEART FAILURE: WHEN TO REFER Navin Rajagopalan, MD Assistant Professor of Medicine University of Kentucky Director, Congestive Heart Failure Medical Director of Cardiac Transplantation
More informationเอกราช อร ยะช ยพาณ ชย
30 July 2016 เอกราช อร ยะช ยพาณ ชย Heart Failure and Transplant Cardiology aekarach.a@chula.ac.th Disclosure Speaker, CME service: Merck, Otsuka, Servier Consultant, non-cme service: Novartis, Menarini
More informationPredicting Major Outcomes after MCSD Implant. Risk Factors for Death, Transplant, and Recovery. James Kirklin, MD David Naftel, PhD
Predicting Major Outcomes after MCSD Implant Risk Factors for Death, Transplant, and Recovery James Kirklin, MD David Naftel, PhD 1 I have no financial disclosures (I am the Principle Investigator for
More informationSurgical Options for Advanced Heart Failure
Surgical Options for Advanced Heart Failure Benjamin Medalion, MD Director, Transplantation and Heart Failure Surgery Department of Cardiothoracic Surgery Rabin Medical Center, Beilinson Hospital Heart
More informationVAD come Destination therapy nell adulto con Scompenso Cardiaco
VAD come Destination therapy nell adulto con Scompenso Cardiaco Francesco Santini Division of Cardiac Surgery, IRCCS San Martino IST University of Genova Medical School, Italy Heart Transplantation is
More informationPostcardiac transplant survival in the current era in patients receiving continuous-flow left ventricular assist devices
Postcardiac transplant survival in the current era in patients receiving continuous-flow left ventricular assist devices Forum Kamdar, MD, a Ranjit John, MD, b Peter Eckman, MD, a Monica Colvin-Adams,
More informationPROVEN. TRUSTED. COMMITTED. HeartWare HVAD System
PROVEN. TRUSTED. COMMITTED. HeartWare HVAD System PROVEN. TRUSTED. COMMITTED. 42% of all heart transplant patients worldwide are bridge to transplant with a VAD. 1 Our commitment to advance the treatment
More informationDiagnosis of Device Thrombosis
Diagnosis of Device Thrombosis Andrew Civitello MD, FACC Medical Director, Heart Transplant Program Director, Fellowship Co-Director, Baylor St. Luke's Medical Center / Texas Heart Institute Trends in
More informationAndrew Civitello MD, FACC
Timing the Transition from Short Term to Long Term Mechanical Circulatory Support Andrew Civitello MD, FACC Medical Director, Heart Transplant Program Director, Fellowship Co-Director, Baylor St. Luke's
More informationOutcomes after stroke complicating left ventricular assist device
http://www.jhltonline.org Outcomes after stroke complicating left ventricular assist device Joshua Z. Willey, MD, MS, a Michael V. Gavalas, MD, b Pauline N. Trinh, MPH, c Melana Yuzefpolskaya, MD, b A.
More informationSubclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study
Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study Meagan Sullivan, PharmD PGY2 Cardiology Pharmacy Resident University of Chicago Medicine
More informationSupplementary Online Content
Supplementary Online Content Inohara T, Manandhar P, Kosinski A, et al. Association of renin-angiotensin inhibitor treatment with mortality and heart failure readmission in patients with transcatheter
More informationI have nothing to disclose.
I have nothing to disclose. Right ventricular failure and need for biventricular support Friedrich Wilhelm Mohr, MD, PhD Munich, August 27, 2012 Male; date of birth: 19.07.1984 Out clinic visit 10/ 2004:
More informationEnd Stage Heart Failure - Time to Bring the Hammer Down
End Stage Heart Failure - Time to Bring the Hammer Down Eric R. Skipper, MD, FACS Chief, Adult Cardiovascular Surgery Surgical Director of Cardiac Transplantation and Mechanical Circulatory Support 2 3
More informationPerioperative Management of the Mechanical Circulatory Support Patient. American Association of Thoracic Surgeons Allied Health Symposium May 4, 2013
Perioperative Management of the Mechanical Circulatory Support Patient American Association of Thoracic Surgeons Allied Health Symposium May 4, 2013 Disclosures None 2012 MFMER slide-2 Objectives Review
More informationMechanical assist patient selection, device selection, and outcomes
Mechanical assist patient selection, device selection, and outcomes Josef Stehlik, MD, MPH Associate Professor of Medicine Medical Director, Heart Transplant Program University of Utah School of Medicine
More informationAdverse Event Not Started
Adverse Event t Started Adverse Event Status Print this Form t Started Please enter the date of the event you are reporting: Please enter a label describing this event: 2014 InterMACS [InterMACS_New] 1
More informationClinical Experience With HeartWare Left Ventricular Assist Device in Patients With End-Stage Heart Failure
ADULT CARDIAC Clinical Experience With HeartWare Left Ventricular Assist Device in Patients With End-Stage Heart Failure Aron Frederik Popov, MD, Morteza Tavakkoli Hosseini, MD, Bartlomiej Zych, MD, Prashant
More informationManagement of Cardiogenic Shock. Dr Stephen Pettit, Consultant Cardiologist
Dr Stephen Pettit, Consultant Cardiologist Cardiogenic shock Management of Cardiogenic Shock Outline Definition, INTERMACS classification Medical management of cardiogenic shock PA catheters and haemodynamic
More informationFirst Experiences With the HeartWare Ventricular Assist System in Children
First Experiences With the HeartWare Ventricular Assist System in Children Oliver Miera, MD, Evgenij V. Potapov, MD, PhD, Matthias Redlin, MD, Alexander Stepanenko, MD, Felix Berger, MD, PhD, Roland Hetzer,
More informationNew Trends and Indications for LVADs
New Trends and Indications for LVADs Mark S. Slaughter, MD Professor and Chief Division of Thoracic and Cardiovascular Surgery University of Louisville Natural History of Heart Failure 100 10 Class III
More informationVentricular Assisting Devices in the Cathlab. Unrestricted
Ventricular Assisting Devices in the Cathlab Unrestricted What is a VAD? A single system device that is surgically attached to the left ventricle of the heart and to the aorta for left ventricular support
More informationDEMYSTIFYING VADs. Nicolle Choquette RN MN Athabasca University
DEMYSTIFYING VADs Nicolle Choquette RN MN Athabasca University Objectives odefine o Heart Failure o VAD o o o o Post Operative Complications Acute Long Term Nursing Interventions What is Heart Failure?
More informationLVADs as a long term or destination therapy for the advanced heart failure
LVADs as a long term or destination therapy for the advanced heart failure Prof. Davor Miličić, MD, PhD University of Zagreb School of Medicine Department of Cardiovascular Diseases University Hospital
More informationIndications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014
Indications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014 Indications for cardiac catheterization Before a decision to perform an invasive procedure such
More informationTotal Artificial Hearts and Implantable Ventricular Assist Devices
Total Artificial Hearts and Implantable Ventricular Assist Devices Policy Number: 7.03.11 Last Review: 12/2018 Origination: 12/2001 Next Review: 12/2019 Policy Blue Cross and Blue Shield of Kansas City
More informationHow to mend a broken heart: transplantation or LVAD?
SCDU DI CARDIOCHIRURGIA Università degli Studi di Torino Ospedale S. Giovanni Battista Direttore: Prof. Mauro Rinaldi How to mend a broken heart: transplantation or LVAD? Massimo Boffini Mauro Rinaldi
More informationRight Ventricular Failure: Prediction, Prevention and Treatment
Right Ventricular Failure: Prediction, Prevention and Treatment 3 rd European Training Symposium for Heart Failure Cardiologists and Cardiac Surgeons University Hospital Bern June 24-25, 2016 Disclosures:
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST Cardiogenic Shock Mechanical Support Eulàlia Roig FESC Heart Failure and HT Unit Hospital Sant Pau - UAB Barcelona. Spain No conflics of interest Mechanical Circulatory
More informationUniversity of Florida Department of Surgery. CardioThoracic Surgery VA Learning Objectives
University of Florida Department of Surgery CardioThoracic Surgery VA Learning Objectives This service performs coronary revascularization, valve replacement and lung cancer resections. There are 2 faculty
More informationThe Who, How and When of Advanced Heart Failure Therapies. Disclosures. What is Advanced Heart Failure?
The Who, How and When of Advanced Heart Failure Therapies 9 th Annual Dartmouth Conference on Advances in Heart Failure Therapies Dartmouth-Hitchcock Medical Center Lebanon, NH May 20, 2013 Joseph G. Rogers,
More informationAcute heart failure: ECMO Cardiology & Vascular Medicine 2012
Acute heart failure: ECMO Cardiology & Vascular Medicine 2012 Lucia Jewbali cardiologist-intensivist 14 beds/8 ICU beds Acute coronary syndromes Heart failure/ Cardiogenic shock Post cardiotomy Heart
More informationMCSD Pump Thrombosis : Industry Perspective
MCSD Pump Thrombosis : Industry Perspective John B. O Connell MD Vice President, Medical Affairs Thoratec Corporation 1 1 Thoratec Asia Pacific Mechanical Circulatory Support (MCS) Conference Agenda 15-17
More informationEcho in Heart Failure
Echo in Heart Failure Karima Addetia, MD Heart Failure: Definition A clinical syndrome that results from impairment of ventricular filling or ejection of blood. Manifestations include dyspnea and fatigue,
More informationEMS: Care of the VAD Patient. Brittany Butzler BSN RN VAD Coordinator Froedtert and the Medical College of WI
EMS: Care of the VAD Patient Brittany Butzler BSN RN VAD Coordinator Froedtert and the Medical College of WI Disclosure No relevant financial relationships by planners or presenters Left Ventricular Assist
More information3/23/2018. Complications of VAD Therapy: Arrhythmias. Disclosures. Agenda. I have no relevant disclosures
March 23, 2018 Complications of VAD Therapy: Arrhythmias Sandeep M. Jani, MD, MPH Associate Directory of Advanced Heart Failure and Population Health MedStar Heart and Vascular Institute - Baltimore Sandeep
More informationOutpatient Treatment of MCS Patient. F. Bennett Pearce, MD Professor of Pediatrics Med Director Heart Transplant COA
Outpatient Treatment of MCS Patient F. Bennett Pearce, MD Professor of Pediatrics Med Director Heart Transplant COA Disclosure Statement I DO NOT HAVE ANY RELEVANT FINANCIAL RELATIONSHIPS WITH ANY COMMERCIAL
More informationAdvanced Heart Failure and Transplant Cardiology
Advanced Heart Failure and Transplant Cardiology Certification Examination Blueprint Purpose of the exam The exam is designed to evaluate the knowledge, diagnostic reasoning, and clinical judgment skills
More informationLeft Ventricular Assist Devices LVAD. North Country EMS Program Agency 3/21/12
Left Ventricular Assist Devices LVAD North Country EMS Program Agency 3/21/12 Objectives Describe indications for and functions of ventricular assist devices (LVAD) Differentiate assessment findings of
More informationHeartWare HVAD System. Instructions for Use
HeartWare HVAD System Instructions for Use Table of Contents 1.0...1 1.1... 1. Indications for Use... 1. Contraindications... 1. Warnings... 1. Precautions... 1. Potential Complications... 1. Pivotal
More informationReadmissions: an unavoidable nemesis
Readmissions: an unavoidable nemesis This presentation was presented at the Thoratec Corporation Economic Summit held on September 30-October 2 in La Jolla, CA. Please note that this presentation and content
More information